Skip to content

MILLENIUM PHARMA

Active Private limited company (pre-2019)founded 1999active for 26 yearsVan Overbekelaan 153, 1083 GanshorenKBO/BCE: BE 0467.724.694 subsidiary of AK Herbo Pharma#8 company by total assets in Ganshoren, Wholesale and retail trade sector
MILLENIUM PHARMA
Follow ReportCompare

Overview

Lifetime

20 annual accounts with figures on one time axis, 26 filings since 2000
peak €476,023 (2019)
€423,867▼ 6.1%
peak €261,358 (2019)
€105,304▼ 17.7%
peak €574,829 (2017)
€288,316▲ 1.9%
€859,686▲ 12.4%
peak 4.6 FTE (2021)
4.3 FTE▼ 2.3%
Board2 names since 2021
1 directorAK Herbo Pharma
Owners
100%AK Herbo Pharma
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Dividend €30,000

Key points

from the 2025 annual accounts

Equity

€288,316 from €574,829 in 2017

Equity fell by 50% in 8 years.

Debts

€859,686 75% of the balance sheet
Financial debts 44%Suppliers 44%Taxes and wages 4%Other 9%

Of this, €499,855 falls due within a year.

Filings

26 annual accounts since 2000
AprilJune31 JulyOctober200020102020

Five of the last ten came late. The 2019 accounts came latest: 31 days after the end of the period.

Checked score

85
Excellent
Financially stronger than 50% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.1% 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025lowest value 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.2%▲ +0.1 percentage points vs 06-2025 08-2025: 0.4%▲ +0.2 percentage points vs 07-2025 09-2025: 0.2%▼ -0.2 percentage points vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.2%● unchanged vs 05-2026 07-2026: 0.3%▲ +0.1 percentage points vs 06-2026 08-2026: 0.7%▲ +0.4 percentage points vs 07-2026highest value 09-2026: 0.4%▼ -0.3 percentage points vs 08-2026 10-2026: 0.4%● unchanged vs 09-2026 11-2026: 0.4%● unchanged vs 10-2026

Financial strength
Average

50-2equity 25.1% of total assets
45-6short-term debt 43.5% · cash 13.0%
80-4return on assets 9.2%

Score breakdown

raises risk
Last filed accounts filed 31 days late; 1 of the last 3 accounts late
Sector: Retail trade (NACE 47)
lowers risk
Founded in 1999
Size: 4.3 FTE, total assets €1.1m
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 41% of them on solvency, 44% on liquidity, 72% on profitability and 45% on growth.

The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 3,818 companies had the same profile as MILLENIUM PHARMA has now. Each dot stands for 10 companies, two years later.

95.1%
were still trading
3.7%
stopped another way
1.0%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more

Another 0.2% stopped without a precise date, possibly only after those two years.

That fits the bankruptcy probability of MILLENIUM PHARMA itself: 0.4% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,818 companies, not a prediction for MILLENIUM PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €24,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 1.53 (1.71 in 2024), above the usual 1.5. Short-term debt is 43.5% and cash 13% of total assets. However, 74.9% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises risk
lowers risk · Founded in 1999
Companies that have existed this long fail less often. How much that weighs depends on the rest of the company's profile.
KBO
raises risk · Last filed accounts filed 31 days late; 1 of the last 3 accounts late
NBB · filings
raises risk · Sector: Retail trade (NACE 47)
KBO
lowers risk · Size: 4.3 FTE, total assets €1.1m
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €288,316
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
31 days late
2024
20 days late
2023
23 days late
2022
46 days early
2021
6 days early
2020
4 days early
2019
31 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 7 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 20 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

AH
AK Herbo Pharma
Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0467724694
1 director appointed, 1 resignation Resignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae · Gazette deed
1 director appointed, 1 resignation Resignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae · Gazette deed
Capital decrease of €297,519.30 to €18,592.01 Capital from €316,111.31 to €18,592.01 · General meeting of 31-07-2018 · Gazette deed
All 35 events

Comparable companies

same main activity, similar in size and age
Company
MILLENIUM PHARMA Ganshoren €1.1m €423,867 25.1% 4.3
APOTHEEK PHARMAGO Nazareth-De Pinte €1.2m €436,367 30.6% 4.6
APOTHEEK ST-JORIS Tielt-Winge €1.1m €396,044 6.4% 4.1
Pharmacie Des Trois Tilleuls Watermael-Boitsfort €1.0m €499,060 38.7% 3.7
Pharmacie Tilman Assesse Assesse €1.1m €362,166 9.1% 4
LOMA PHARMA Izegem €1.2m €420,865 31.2% 3.9
PHARMACIE LIPPINOIS Brunehaut €1.4m €423,532 30.2% 4

These companies have the same main activity as MILLENIUM PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1m and €1.4m, founded between 1999 and 2003.

Official details

Source: KBO
Status
Active since 30-11-1999Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 1 other
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.093.980.0751083 Ganshoren, since 14-09-2000
Financial year end
31 December
Peppol
Reachable since 11-12-2025
Company details

Annual accounts 2025

€423,867▼ 6.1%
≈ €1.5mestimated
€105,304▼ 17.7%
€288,316▲ 1.9%
€1.1m▲ 9.5%
Employeeson 31-12-2025
4▼ 20.0%
Filing
Filed on 31-08-2026
Financials

Insights on MILLENIUM PHARMA

MILLENIUM PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €178,837 in 2006 to €423,867 in 2025.

AK Herbo Pharma holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 31-08-2026, 31 days late
€423,867
▼ 6.1%
€133,084
▼ 18.1%
€105,304
▼ 17.7%
€262,777
▲ 1.7%
25.1%
▼ 1.9 percentage points
1.53
▼ 0.19

The turnover shown is an estimate from the gross margin.

Turnover ≈ €1.5m. Estimated: probably between €1.2m and €2.4m.

In the rankings #8 company by total assets in Ganshoren, Wholesale and retail trade sector

Balance sheet

balance sheet total €1.1m on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

25.1%

Higher than 37% of 12,853 companies in 2025.

1.53

Higher than 50% of 12,643 companies in 2025.

9.2%

Higher than 70% of 12,717 companies in 2025.

MILLENIUM PHARMA Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half · Staff: middle half

Staff

€57,375

Staff costs divided by the average number of full-time equivalents.

-1 person

people who joined people who left

In 2025, nobody joined and 1 person left.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
Balance sheet: assets
20/58 1.1m1.0m877,622857,562729,817667,196736,828707,666860,917783,945769,030733,295754,520861,179814,274701,646625,991600,903647,4941.8m
21/28 385,370427,825238,491204,660218,125224,759231,206391,893400,983327,176321,393323,359329,925340,489348,330356,568348,952362,163369,434394,316
21 -----------------2,0394,0788,156
22/27 385,370427,825238,491204,660218,125224,759231,206242,393251,483177,676171,893173,859180,425190,989198,830207,068199,452210,624215,856236,660
22 163,241171,136179,030186,925194,819202,714210,608218,803222,597156,445162,281168,118173,955179,791185,628190,004192,835198,371203,907214,979
23 221,312254,90155,64011,31414,52217,78718,72719,97922,88712,7162,3223,1173,9114,7064,9385,6774,9798,3836,91713,415
24 8171,7883,8216,4228,7834,2581,8713,6115,9998,5157,2902,6242,5596,4928,26411,3871,6383,8705,0328,266
28 -------149,500149,500149,500149,500149,500149,500149,500149,500149,500149,500149,500149,500149,500
29/58 762,632620,163639,131652,901511,693442,438505,622315,773459,935456,769447,637409,936424,595520,690465,944345,078277,039238,740278,0601.4m
29 --------139,000135,000125,000---------
291 --------139,000135,000125,000---------
3 191,556192,336177,475155,043124,066116,661107,868119,837104,95296,53789,61791,98783,71082,03573,96870,28862,17266,44270,38276,599
30/36 191,556192,336177,475155,043124,066116,661107,868119,837104,95296,53789,61791,98783,71082,03573,96870,28862,17266,44270,38276,599
40/41 419,576289,231243,371252,240199,24981,06085,34482,07876,01785,72396,904212,861216,633294,253282,161224,955187,312165,501195,5621.3m
40 165,866154,284127,892218,593161,77578,45980,49077,66576,01775,87982,43287,13290,985136,527152,46583,50264,53449,74088,6601.1m
41 253,709134,947115,47933,64737,4742,6014,8534,413-9,84414,472125,729125,648157,726129,696141,453122,778115,761106,902157,931
50/53 -----59798,4004,2863,7974,240---------
54/58 149,706135,054217,401244,592187,742236,371298,95399,191122,590123,617126,890105,088124,252144,402109,81549,83527,5556,79712,1163,443
490/1 1,7943,5428841,0276368,28713,3786,26713,09012,0964,986---------
Balance sheet: equity and liabilities
10/49 1.1m1.0m877,622857,562729,817667,196736,828707,666860,917783,945769,030733,295754,520861,179814,274701,646625,991600,903647,4941.8m
10/15 288,316283,011254,991263,873219,758495,344392,514302,656574,829544,986492,930447,55185,162364,614338,633275,700225,393191,030160,130295,278
10/11 6,2006,2006,2006,2006,2006,2006,2006,200303,717303,717303,717303,7166,1976,1976,1976,1976,1976,1976,1976,197
100 ------18,59218,592316,111316,111316,111316,11118,59218,59218,59218,59218,59218,59218,59218,592
101 ------12,39212,39212,39512,39512,39512,39512,39512,39512,39512,39512,39512,39512,39512,395
13 117,061117,061117,061117,061117,061146,813146,81356,95431,61131,61131,61131,6111,8591,8591,8591,8591,8591,8591,8591,859
130/1 1,8591,8591,8591,8591,85931,611--------------
130 ------31,61131,61131,61131,61131,61131,6111,8591,8591,8591,8591,8591,8591,8591,859
1311 1,8591,8591,8591,8591,85931,611--------------
133 115,201115,201115,201115,201115,201115,201115,20125,343------------
14 165,055159,751131,730140,61296,497342,332239,501239,501239,501209,658157,603112,22477,106356,558330,577267,644217,337182,974152,074287,222
16 -----------5,0005,00050,88650,88612,50012,5007,5007,500-
160/5 -----------5,0005,00050,88650,88612,50012,5007,5007,500-
17/49 859,686764,977622,631593,689510,060171,852344,315405,010286,088238,960276,100280,744664,358445,679424,755413,446388,098402,373479,8641.5m
17 359,158403,106214,072196,458215,70816,42323,84035,36552,55223,96733,56342,97460,42083,336120,222164,093205,769245,219282,565351,392
170/4 359,158403,106214,072196,458215,70816,42323,84035,36552,55223,96733,56342,97460,42083,336120,222164,093205,769245,219282,565351,392
42/48 499,855361,870408,559397,230294,352155,429320,475369,645233,536214,956242,537237,770603,938362,343304,533249,353182,329157,154197,2991.1m
42 43,94842,78530,75519,24919,1187,41611,52617,18727,5039,59629,41117,44624,07137,99544,72342,02039,45037,34635,34824,393
43 17,500037,75327,55010,8245,3425,3435,3424,0044,0134,013-1,70720,09518,83312,55512,56312,85812,5692,272
430/8 17,500037,75327,55010,8245,3425,3435,3424,0044,0134,013-1,70720,09518,83312,55512,56312,85812,5692,272
44 376,614176,878200,887255,236211,32290,65296,850199,015172,032162,713179,251182,273215,319295,064208,002175,174120,860100,230147,474997,053
440/4 376,614176,878200,887255,236211,32290,65296,850199,015172,032162,713179,251182,273215,319295,064208,002175,174120,860100,230147,474997,053
45 30,48241,37838,89345,19553,08752,01935,25622,53522,31132,36928,10036,98165,3229,18932,97519,6049,4566,7201,90871,775
450/3 04,3556,97012,98831,18330,90314,0401,7095,77915,4118,04024,95642,636-28,17313,3853,2825461,50871,775
454/9 30,48237,02231,92332,20721,90421,11621,21720,82616,53116,95820,06012,02522,6869,1894,8026,2196,1746,174400-
47/48 31,311100,830100,27050,000--171,500125,5667,6866,2651,7631,070297,519------12,910
492/3 673--------37----------
Income statement
76A ------198,992---30,991-1,5425,4302,677-1,0721,598-4,546
9900 423,867451,184373,839371,175303,605326,498476,023218,039195,682241,060191,198211,051181,412175,343202,665125,063101,79379,00976,253178,837
62 246,713243,946219,564221,974179,034169,608168,331165,598134,633140,830137,54594,226131,194112,24937,26119,30213,336511400-
630 43,77038,97022,55714,57912,90213,34014,00413,49213,97411,4399,7718,09411,19911,07210,48212,36713,21113,21112,367-
635/8 -------------45,886-38,386-5,000---
640/8 2995,8224,5083,80915,0374,8205,2473,4323,2196,3525,4873,8443,9653,9285,4484,6374,0023,9503,0381,319
66A ----------2,202---------
9901 133,084162,446127,210130,81396,632138,731288,44135,51843,85782,43938,394104,88780,94048,094111,08888,75766,24461,33760,448177,518
75/76B 5414102,7348383144,0693,3863,5083,7943,6371,267555434169181164250-
75 5414102,7348383144,0693,3863,5083,7943,6371,267555434169181164250-
65/66B 15,02313,2778,0243,0093,2691,4362,5861,9612,5578,9095,4016,0446,9879,61911,55713,31114,87416,84919,4101,403
65 15,02313,2778,0243,0093,2691,4362,5861,9612,5578,9095,4016,0446,9879,61911,55713,31114,87416,84919,4101,403
9903 118,603149,578121,921127,81293,401137,608289,92436,94344,80877,32365,419100,11076,05044,339102,37775,62752,45846,09041,288180,661
67/77 13,29921,55830,80333,69728,98834,77828,56611,60014,96425,26820,04135,24024,92518,35839,44425,32018,09515,19011,768-
9904 105,304128,02191,11894,11564,414102,830261,35825,34329,84352,05545,37964,87051,12525,98162,93350,30734,36330,90029,520180,661
9905 105,304128,02191,11894,11564,414102,830261,35825,34329,84352,05545,37964,87051,12525,98162,93350,30734,36330,90029,520180,661
Appropriation of the result
9906 265,055259,751231,730190,612406,745342,332500,859264,844239,501209,658157,603141,976407,683356,558330,577267,644217,337182,974152,074287,222
14P 159,751131,730140,61296,497342,332---------------
791/2 ----29,752---------------
691/2 ------89,85825,343---29,752--------
6920 -----------29,752--------
6921 ------89,85825,343------------
694/7 100,000100,000100,00050,000340,000-171,500-----330,577-------
694 30,00050,000100,00050,000340,000-171,500-----330,577-------
695 70,00050,000------------------
Social balance sheet
9087 4.34.44.34.34.63.63.43.43.232.82.722.510.90.80.20.1-
Hours worked1013 6,1786,5046,0646,8106,4925,6975,9905,9754,1794,4884,2723,2123,4393,0711,7231,5791,60230456-
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The accounts for 6 older financial years (2000-2005) were filed as documents without figures as data, scans for example.

The notes to these accounts have 21 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 31-08-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2025 annual accounts filed 31 days after the deadline. Filed on 31 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00486108.

Financial year Type Filed Reference Document
31-12-2025 abbreviated format 31-08-2026 2026-00486108 PDF
31-12-2024 full format 20-08-2025 2025-00385170 PDF
31-12-2023 full format 23-08-2024 2024-00371514 PDF
31-12-2022 full format 15-06-2023 2023-00140488 PDF
31-12-2021 full format 25-07-2022 2022-20230526 PDF
31-12-2020 full format 27-07-2021 2021-40000323 PDF
31-12-2019 full format 31-08-2020 2020-47000511 PDF
31-12-2018 full format 12-08-2019 2019-45600230 PDF
31-12-2017 full format 25-07-2018 2018-37400433 PDF
31-12-2016 full format 31-07-2017 2017-37700476 PDF
31-12-2015 full format 02-08-2016 2016-38500190 PDF
31-12-2014 full format 30-09-2015 2015-61200467 PDF
31-12-2013 full format 30-09-2014 2014-60900312 PDF
31-12-2012 full format 30-09-2013 2013-59900088 PDF
31-12-2011 full format 26-09-2012 2012-57400599 PDF
31-12-2010 full format 29-02-2012 2012-04800144 PDF
31-12-2009 full format 18-11-2010 2010-60700301 PDF
31-12-2008 full format 31-10-2009 2009-83500149 PDF
31-12-2007 full format 31-10-2008 2008-80800041 PDF
31-12-2006 full format 28-08-2007 2007-61300362 PDF
31-12-2005 full format 27-07-2006 2006-55002770 PDF
31-12-2004 full format 27-07-2005 2005-57204381 PDF
31-12-2003 full format 30-09-2004 2004-68701583 PDF
31-12-2002 full format 30-06-2003 2003-34202237 PDF
31-12-2001 full format 12-07-2002 2002-37200559 PDF
31-12-2000 full format 04-07-2001 2001-33304710 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
176,855201,416149,767145,392109,534152,071302,44449,01057,83093,87848,165112,98192,13959,166121,570101,12479,45574,54872,815-
149,075166,991113,675108,69477,315116,171275,36238,83543,81763,49455,15072,96462,32437,05373,41562,67447,57444,11141,887-
1,315228,30556,3881,1159,4066,8932,8174,40287,78018,54312,0331,5286353,2312,24419,98305,9406798,424
14,651-82,347-27,19056,849-48,629-62,582199,762-23,399-1,027-3,27421,802-19,164-20,15034,58759,98022,28020,758-5,3198,673-
262,777258,292230,572255,671217,341287,009185,147-53,872226,399241,813205,100172,166-179,343158,347161,41195,72594,71081,58680,761252,354
25.1%27.0%29.1%30.8%30.1%74.2%53.3%42.8%66.8%69.5%64.1%61.0%11.3%42.3%41.6%39.3%36.0%31.8%24.7%16.8%
1.531.711.561.641.742.851.580.851.972.121.851.720.701.441.531.381.521.521.411.23
1.141.181.131.251.322.101.240.531.521.681.481.340.561.211.291.101.181.101.051.16
2.982.702.442.252.320.350.881.340.500.440.560.637.801.221.251.501.722.113.004.94
36.5%45.2%35.7%35.7%29.3%20.8%66.6%8.4%5.2%9.6%9.2%14.5%60.0%7.1%18.6%18.2%15.2%16.2%18.4%61.2%
9.2%12.2%10.4%11.0%8.8%15.4%35.5%3.6%3.5%6.6%5.9%8.8%6.8%3.0%7.7%7.2%5.5%5.1%4.6%10.3%
11.7715.1718.6748.3233.51---------------

EBIT margin: not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date45556
full-time33333
part-time12223
in full-time equivalents3.84.64.34.34.6
4.34.44.34.34.6
On a permanent contract45556
Joined0----
Left1----

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€1,315€228,305€56,388€1,115€9,406
Financial fixed assets€0----
€43,770€38,970€22,557€14,579€12,902

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on MILLENIUM PHARMA

The operating result for 2025 is 18% lower than in 2024.

Debt's share of the balance-sheet total rises from 73.0% to 74.9%. Equity and debt are higher.

Board & ownership

Board

1 director, last change in 2022
AK Herbo Pharma BV
Director
appointed by deed of 10-12-2021
listed in the 2025 annual accounts, filed on 31-08-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“Sont nommés au postes d'administrateurs: AK HERBO PHARMA SRL (BE0770.728.643) qui désigne comme représentant permanent: -Monsieur Ali Kassem…”
deed of 10-12-2021

Office holders in the KBO →

Mandates through the years

2 names, the dashed line is today
AK Herbo Pharma
Director
Chantal De Saeger
Director
BoardEarliermandate already running before its first mention
Mandates as a list
  • AK Herbo Pharma
    • Director, appointed by deed of 10-12-2021, still in office
  • Chantal De Saeger
    • Director, until 10-12-2021
    • Director, until 06-01-2022

See the board, name and registered office on a given date →

Control

Parent
AK Herbo Pharma
Equity €466,258
Profit €61,600 in 2025 (loss €18,337 in 2024)
Checked score 55
Source: accounts AK Herbo Pharma 2025
100%
This company
MILLENIUM PHARMA
Equity €288,316
Profit €105,304 in 2025

Capital

Contribution
€6,200
Source
2025 annual accounts

Owners through the years

as the annual accounts name them
AK Herbo Pharma
100%
100%
Owners as a list

Source: lists of holdings in the owners' accounts

Network & group

Holdings

own 2018 accounts, the bar shows equity in euros
This companyMILLENIUM PHARMA1 holding, 1 country 2018 accounts

Belgium 1 Equity Result

  • BE IMMO HD75%no longer active €97,704 result €7,144

Source: list of holdings in its own 2018 accounts. Every holding stands with its own latest accounts.

Parent

AK Herbo Pharma
0770.728.643 · 100% of the shares · equity €466,258 · profit €61,600 (2025)
Checked score 55

At the same address

Van Overbekelaan 153, 1083 Ganshoren · 2 other companies
SMART ENERGY HJ
establishment since 13-09-2013 · founded in 2013
 total assets €370,011 (2025)
0538.924.179
Vereniging van de mede-eigenaars van het gebouw gelegen te 1083 Ganshoren, aan de hoek van Sint Martinuskerkstraat en Van Overbeeklaan 153
registered office since 18-01-1996
 founded in 1996
0690.846.569

Holdings through the years

2006 to 2018
Holdings through the years
Name2006200720082009201020112012201320142015201620172018
IMMO H.D. 75%

Source: list of holdings in its own accounts

Connections & network

1 current director
Depth

The network lets you explore the ties of MILLENIUM PHARMA.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

35 events since 1999

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed NBBabbreviated format · 31 days late
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0467724694
Annual accounts 2024 filed PDFfull format · 20 days late
2024
Annual accounts 2023 filed PDFfull format · 23 days late
2023
Annual accounts 2022 filed PDFfull format · 46 days before the deadline
2022
Annual accounts 2021 filed PDFfull format · 6 days before the deadline
1 director appointed, 1 resignationResignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae5 points ▸

Open the deed in the Belgian Official Gazette

2021
1 director appointed, 1 resignationResignation: Chantal De Saeger · Appointment: AK HERBO PHARMA SRL · Permanent representatives: Ali Kassem and Haouzi Sanae5 points ▸

Open the deed in the Belgian Official Gazette

Annual accounts 2020 filed PDFfull format · 4 days before the deadline
2020
Annual accounts 2019 filed PDFfull format · 31 days late
2019
Highest result from 2006 to 2025 net €261,358 ▲931% The operating result of €288,441 and the net result of €261,358 are both a record.
Annual accounts 2018 filed PDFfull format · 12 days late
2018
Capital decrease of €297,519.30 to €18,592.01Capital from €316,111.31 to €18,592.01 · General meeting of 31-07-20183 points ▸
  • General meeting, 31-07-2018
  • Capital decrease, €297,519.30
  • Amendment of the articles, article 5
  • The deed holds 1 more point.

Open the deed in the Belgian Official Gazette

Annual accounts 2017 filed PDFfull format · 6 days before the deadline
2017
Annual accounts 2016 filed PDFfull format · on the deadline day
2016
Equity above €500,000 equity €544,986 ▲10.6% Equity rises from €492,930 to €544,986.
Annual accounts 2015 filed PDFfull format · 2 days late
2015
Annual accounts 2014 filed PDFfull format · 61 days late
2014
Liquidity more than doubled current ratio 1.72 The current ratio rises from 0.70 to 1.72. Short-term debt falls from €603,938 to €237,770.
Annual accounts 2013 filed PDFfull format · 61 days late
2013
Annual accounts 2012 filed PDFfull format · 61 days late
2012
Annual accounts 2011 filed PDFfull format · 57 days late
Annual accounts 2010 filed PDFfull format · 213 days late
2010
Annual accounts 2009 filed PDFfull format · 110 days late
2009
Annual accounts 2008 filed PDFfull format · 92 days late
2008
Annual accounts 2007 filed PDFfull format · 92 days late
2007
Annual accounts 2006 filed PDFfull format · 28 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2004
Annual accounts 2003 filed PDFfull format
2003
Annual accounts 2002 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2001
Annual accounts 2000 filed PDFfull format
2000
First establishment Van Overbekelaan 153, Ganshoren
1999
Incorporation published on 09-12-1999

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

MILLENIUM PHARMA was incorporated on 30 November 1999.1 Total assets rose from €707,666 in 2018 to €1.1m in 2025 and headcount from 3.4 to 4.3 full-time equivalents.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2018 and 2025

Company details

Identity

Enterprise number
0467.724.694
VAT number
BE 0467.724.694
Peppol ID
0208:0467724694
Other Peppol ID
9925:BE0467724694
LEI code
967600XJCCZL6I4TEP14 no longer live in the LEI register
Legal form
Private limited company (pre-2019)
Status
Active, normal situation
Founded
30-11-1999
Financial year
ends on 31 December
Peppol
Reachable since 11-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
MILLENIUM PHARMA in French
Entity type
Legal entity
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Van Overbekelaan 153, 1083 Ganshoren”
deed of 10-12-2021 (in French)

Activities

NACEBEL 2025
VAT activities
47730 Retail sale of pharmaceutical products main activity
47750 Retail sale of cosmetics and toilet articles
Social security (RSZ) activities
47730 Retail sale of pharmaceutical products main activity
Joint committees annual accounts 2025
JC 313 Pharmacies and pricing offices
Codes under NACEBEL 2008
VAT activities
47730 Retail trade main activity
47750 Retail trade
Social security (RSZ) activities
47730 Retail trade main activity
Codes under NACEBEL 2003
VAT activities
52310 main activity
52330
Social security (RSZ) activities
52310 main activity

Registered office and establishments

1 establishment
Establishment Since Unit numberFASFC approval
Van Overbekelaan 153 registered office 1083 Ganshoren 14-09-2000 2.093.980.075 Pharmacy (food >3 months)

Buildings and parcels at the address

Ground area
305 m²
Buildings
173 m²
Volume, LiDAR
2,359 m³
Tallest building
15.3 m
Buildings to scale, each on its own parcel
173 m², 15.3 m 173 m², 15.3 m

Location

registered office establishment The establishment unit on the map
3 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
21008A0143/00C005305 m² 1 · 173 m² 15.3 m · 5

Recognitions

Food safety, FASFC

1 site
Ganshorenunit number 2.093.980.075
1 permission
Pharmacy (food >3 months) · since 18-02-2010

Source: FAVV-AFSCA, open data, updated on 02-11-2026

We would like to set cookies. That happens only with your consent. What we measure